United Therapeutics Corporation
NASDAQUnited Therapeutics heads into the first week of September with short sellers retreating and options traders leaning modestly bullish — yet the dominant data point is a steady stream of planned CEO stock sales running against a Street consensus that still sees meaningful upside. The insider angle is the sharpest signal this week. CEO Martine Rothblatt sold roughly 9,500 shares on…
UTHR cost to borrow surges 167% in one week to 0.44%, though still remains near historic lows as massive availability cushions short sellers.
Snapshot as of 20 Sept 2026
United Therapeutics heads into the first week of September with short sellers retreating and options traders leaning modestly bullish — yet the dominant data point is a steady stream of planned CEO stock sales running…
United Therapeutics is heading into the back half of May with a notable divergence: short sellers are retreating at the same time a key analyst is turning more bullish. Short interest has been unwinding steadily for a…
United Therapeutics enters the post-earnings period with an unusual alignment: options traders turned the most bullish they've been all year on the day the CEO and CFO were selling stock at the open. The insider angle…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for UTHR — free to start on ORTEX.
Sign up for free →Open UTHR on ORTEX